Dr Gandy heads the Stem Cell Research Consortium funded by the Cure Alzheimer’s Fund (CAF). The Consortium consists of six institutions that plan to directly investigate, for the first time, brain cells in petri dishes from individual patients who have the common form of AD.
Dr Gandy is working with Dr Noggle’s team to reprogram skin cells from AD patients into brain cells using stem cell technology. The research team will obtain and monitor adult AD brain cells, providing not only a way to study the causes of the disease but also a system for discovering potentially effective drugs. The strategy has been nicknamed “the patient-specific disease in a dish” and enables studies on a time scale of minutes or hours, compared with mouse model testing, which routinely requires nine months to one year.
“This approach is one of our best shots at understanding common forms of Alzheimer’s. Once defects are identified, we can use these same brain cells to screen for new drugs,” said Dr. Gandy, Professor of Neurology and Psychiatry and Director of the Center for Cognitive Health at Mount Sinai. “This breakthrough technology will enable us to identify genetic and biochemical differences underlying the most common form of Alzheimer’s disease.”
In collaboration with Mary Sano, PhD, Professor of Psychiatry and Director of the Mount Sinai Alzheimer’s Disease Research Center (ADRC), Dr Gandy plans to select carefully characterized patients and healthy participants from the ADRC who will have skin biopsies and will also undergo brain scans to detect the amount of amyloid plaque, the hallmark of AD, present in the brain. Samples will also be collected from a skin cell bank at the National Institutes of Health. The scans will be used to confirm AD, the risk for developing AD, and whether a brain is amyloid-free.
Dr Noggle will reprogram these skin cells into the various cell types that make up the brain, employing theNYSCF Global Stem Cell Array, a breakthrough automated robotic technology that produces standardized stem cell lines. Results are specific to the patient’s genetic makeup, allowing researchers to uncover Alzheimer’s-related changes at an individual level and to track changes that might otherwise go undiscovered.
“Having all the cell types together in the same dish enables us to mimic as closely as possible the normal and the diseased adult human brain,” said Dr. Gandy. “In these mixed cultures, we will study the roughly three-dozen genes that have been linked to AD to see if any are dysfunctional in such a way as to cause one or more known features of the disease.”
To encourage international collaboration in Alzheimer’s treatment, consortium researchers will create a stem cell bank that can be accessed globally to accelerate drug screening worldwide. This collaboration is an example of NYSCF's commitment to work with global collaborators to advance research.
"We can, for the first time, test drugs across a large, diverse population of Alzheimer's patients, using only their cells. This stem cell resource will embolden scientific investigations and accelerate bench to beside delivery of new treatments," said Dr. Noggle. “We’re incredibly excited to be working with Dr Gandy and fellow collaborators to find a cure for Alzheimer’s disease.”
Other organizations involved in the Consortium are Hadassah University Medical Center, Harvard Medical School and Massachusetts General Hospital, Harvard University Stem Cell Institute, and The Rockefeller University, who is pursuing related research separately funded by CAF.